Faculty, Staff and Student Publications
Publication Date
4-1-2023
Journal
Immunotherapy
Abstract
Introduction: Immune checkpoint inhibitor-associated diabetes mellitus (ICI-DM) is a rare adverse event. In this study, we characterize clinical outcomes of patients with ICI-DM and evaluate survival impact of this complication on melanoma patients.
Research design & methods: We conducted a retrospective review of 76 patients diagnosed with ICI-DM from April 2014 to December 2020.
Results: 68% of patients presented in diabetic ketoacidosis, 16% had readmissions for hyperglycemia, and hypoglycemia occurred in 70% of patients after diagnosis. Development of ICI-DM did not impact overall survival or progression-free survival in melanoma patients.
Conclusion: Development of ICI-DM is associated with long-term insulin dependence and pancreatic atrophy; the use of diabetes technology in this patient population can help improve glycemic control.
Keywords
Humans, Immune Checkpoint Inhibitors, Diabetes Mellitus, Melanoma, Retrospective Studies, diabetic ketoacidosis, hypoglycemia, immune checkpoint inhibitor, insulin-dependent diabetes, pancreatic atrophy
DOI
10.2217/imt-2021-0316
PMID
37013834
PMCID
PMC10088048
PubMedCentral® Posted Date
4-4-2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Biochemical Phenomena, Metabolism, and Nutrition Commons, Bioinformatics Commons, Biomedical Informatics Commons, Endocrine System Diseases Commons, Endocrinology, Diabetes, and Metabolism Commons, Immunotherapy Commons, Oncology Commons